Kimia Biosciences Ltd vs Vaishali Pharma Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Kimia Biosciences Ltd is ₹ 35.05 as of 05 May 15:30 . The P/E Ratio of Kimia Biosciences Ltd changed from 35.1 on March 2021 to 20.9 on March 2025 . This represents a CAGR of -9.85% over 5 yearsThe P/E Ratio of Vaishali Pharma Ltd changed from 32.9 on March 2021 to 209.7 on March 2025 . This represents a CAGR of 44.84% over 5 years The Market Cap of Kimia Biosciences Ltd changed from ₹ 179.55 crore on March 2021 to ₹ 201.13 crore on March 2025 . This represents a CAGR of 2.30% over 5 yearsThe Market Cap of Vaishali Pharma Ltd changed from ₹ 171.9 crore on March 2021 to ₹ 134.85 crore on March 2025 . This represents a CAGR of -4.74% over 5 years The Revenue of Kimia Biosciences Ltd is ₹ 0 crore as of Jun '25 .The Revenue of Vaishali Pharma Ltd is ₹ 24.59 crore as of Jun '25 . The EBITDA of Kimia Biosciences Ltd is ₹ 0 crore as of Jun '25 .The EBITDA of Vaishali Pharma Ltd is ₹ 2.21 crore as of Jun '25 . The Net Profit of Kimia Biosciences Ltd is ₹ 0 crore as of Jun '25 .The Net Profit of Vaishali Pharma Ltd is ₹ 1.28 crore as of Jun '25 . The Dividend Payout of Kimia Biosciences Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Vaishali Pharma Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Kimia Biosciences Ltd

Kimia Biosciences Limited, formerly known Laurel Organics Limited was incorporated in September, 1993.
The Company has own manufacturing of Bulk Drugs-APIs at its plant located at Gurgaon, Haryana.
The name of the Company was changed from 'Laurel Organics Limited' to 'Kimia Biosciences Limited' w.e..f 4 January, 2019.
Since then, it engages in the business of Pharmaceutical products. The company set up a bulk drug manufacturing unit at Gurgaon, Haryana, at a project cost of Rs 10.41 cr.
It came out with a public issue in Feb.'95 to part-finance the project.

About Vaishali Pharma Ltd

Vaishali Pharma Limited was originally incorporated as a Private Limited Company with the name 'Vaishali Pharma Private Limited' on 25th, April 2008.
On July 01, 2008 the Company acquired the business of proprietorship concerns of its Promoter Mr. Atul Vasani viz.
M/s.
Vaishali Pharmachem through Business Assignment agreement.
Consequently, the business of said Proprietorship Firm merged into Vaishali Pharma Private Limited.

FAQs for the comparison of Kimia Biosciences Ltd and Vaishali Pharma Ltd

Which company has a larger market capitalization, Kimia Biosciences Ltd or Vaishali Pharma Ltd?

Market cap of Kimia Biosciences Ltd is 165 Cr while Market cap of Vaishali Pharma Ltd is 100 Cr

What are the key factors driving the stock performance of Kimia Biosciences Ltd and Vaishali Pharma Ltd?

The stock performance of Kimia Biosciences Ltd and Vaishali Pharma Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Kimia Biosciences Ltd and Vaishali Pharma Ltd?

As of May 5, 2026, the Kimia Biosciences Ltd stock price is INR ₹35.05. On the other hand, Vaishali Pharma Ltd stock price is INR ₹7.73.

How do dividend payouts of Kimia Biosciences Ltd and Vaishali Pharma Ltd compare?

To compare the dividend payouts of Kimia Biosciences Ltd and Vaishali Pharma Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.